Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis

Journal of Clinical Virology

Volumn 65, Issue , 2015, Pages 26-31

  Oliveira, Danielle B L ^a   Iwane, Marika K ^b   Prill, Mila M ^b   Weinberg, Geoffrey A ^c   Williams, John V ^d   Griffin, Marie R ^d   Szilagyi, Peter G ^c   Edwards, Kathryn M ^d   Staat, Mary A ^e   Hall, Caroline B ^c   Durigon, Edison L ^a   Erdman, Dean D ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Palivizumab resistance; Pyrosequencing; Respiratory syncytial virus

Indexed keywords

NUCLEOTIDE; PALIVIZUMAB; PRESCRIPTION DRUG; RESPIRATORY SYNCITIAL VIRUS F PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHILD; CHILDHOOD DISEASE; DRUG BINDING SITE; FEVER; GENE SEQUENCE; HOSPITALIZED CHILD; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOPROPHYLAXIS; INTERVIEW; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MIXED INFECTION; MOLECULAR TYPING; MUTATIONAL ANALYSIS; NONHUMAN; NOSE SMEAR; NUCLEIC ACID BASE SUBSTITUTION; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT DISEASE; SANGER SEQUENCING; SEQUENCE ANALYSIS; THROAT CULTURE; UNITED STATES; VIRUS CHARACTERIZATION; VIRUS MUTATION; DNA SEQUENCE; DRUG EFFECTS; FEMALE; GENETICS; MALE; MUTATION; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TIME; VIROLOGY;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; MALE; MUTATION; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SEQUENCE ANALYSIS, DNA; TIME FACTORS; UNITED STATES;

EID: 84924341595     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.01.016     Document Type: Article

References (21)

1. Hall C.B., Simoes E.A., Anderson L.J. Clinical and epidemiologic features of respiratory syncytial virus. Curr. Top. Microbiol. Immunol. 2013, 372:39-57.
2. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
3. Beeler J.A., van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 1989, 63:2941-2950.
4. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., Dormitzer M., O'Grady J., Koenig S., Tamura J.K., Woods R., Bansal G., Couchenour D., Tsao E., Hall W.C., Young J.F. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997, 176:1215-1224.
5. Crowe J.E., Firestone C.Y., Crim R., Beeler J.A., Coelingh K.L., Barbas C.F., Burton D.R., Chanock R.M., Murphy B.R. Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Virology 1998, 252:373-375.
6. Anon Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
7. Shadman K.A., Wald E.R. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin. Biol. Ther. 2011, 11:1455-1467.
8. Domingo E., Holland J. Mutation rates and rapid evolution of RNA viruses. The Evolutionary Biology of Viruses 1994, 161-184. Raven Press, New York. S. Morse (Ed.).
9. Zhao X., Chen F.P., Sullender W.M. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 2004, 318:608-612.
10. Zhao X., Sullender W.M. In vivo selection of respiratory syncytial viruses resistant to palivizumab. J. Virol. 2005, 79:3962-3968.
11. Zhu Q., McAuliffe J.M., Patel N.K., Palmer-Hill F.J., Yang C.F., Liang B., et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J. Infect. Dis. 2011, 203:674-682.
12. Adams O., Bonzel L., Kovacevic A., Mayatepek E., Hoehn T., Vogel M. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin. Infect. Dis. 2010, 51:185-188.
13. Papenburg J., Carbonneau J., Hamelin M.È., Isabel S., Bouhy X., Ohoumanne N., Déry P., Paes B.A., Corbeil J., Bergeron M.G., De Serres G., Boivin G. Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010. Emerg. Infect. Dis. 2012, 18:120-124.
14. Boivin G., Caouette G., Frenette L., Carbonneau J., Ouakki M., De Serres G. Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. J. Clin. Virol. 2008, 42:52-57.
15. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., Auinger P., Griffin M.R., Poehling K.A., Erdman D., Grijalva C.G., Zhu Y., Szilagyi P. The burden of respiratory syncytial virus infection in young children. New Engl. J. Med. 2009, 360:588-598.
16. Fry A.M., Chittaganpitch M., Baggett H.C., Peret T.C., Dare R.K., Sawatwong P., Thamthitiwat S., Areerat P., Sanasuttipun W., Fischer J., Maloney S.A., Erdman D.D., Olsen S.J. The burden of hospitalized lower respiratory tract infection due to respiratory syncytial virus in rural Thailand. PLoS ONE 2010, 5:e15098.
17. Xia Q., Zhou L., Peng C., Hao R., Ni K., Zang N., Ren L., Deng Y., Xie X., He L., Tian D., Wang L., Huang A., Zhao Y., Zhao X., Fu Z., Tu W., Liu E. Detection of respiratory syncytial virus fusion protein variants between 2009 and 2012 in China. Arch. Virol. 2014, 159:1089-1098.
18. Benzi F., Vanni I., Cassina G., Ugolotti E., Di Marco E., Cirillo C., Cristina E., Morreale G., Melioli G., Malnati M., Biassoni R. Detection of ganciclovir resistance mutations by pyrosequencing in HCMV-infected pediatric patients. J. Clin. Virol. 2012, 54:48-55.
19. Ronaghi M., Karamohamed S., Pettersson B., Uhlén M., Nyrén P. Real-time DNA sequencing using detection of pyrophosphate release. Anal. Biochem. 1996, 242:84-89.
20. Duwe S., Schweiger B.J. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. Virol. Methods 2008, 153:134-141.
21. Carroll K.N., Griffin M.R., Edwards K.M., Ali A., Zhu Y., Iwane M.K., Szilagyi P.G., Staat M.A., Stevens T.P., Hall C.B., Williams J.V., Hartert T.V. Adherence to guidelines for respiratory syncytial virus immunoprophylaxis among infants with prematurity or chronic lung disease disease in three United States counties. Pediatr. Infect. Dis. J. 2012, 31:e229-e231.